The DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
Open accessAbstract
Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA mutations, and is approved for treatment in ovarian cancer, with promising clinical activity against other HR defective tumors including breast and prostate cancers. Three PARP inhibitors have been FDA approved, while another two have shown promising activity and are in late stage development. Nonetheless, both primary and secondary resistance to PARP inhibition have led to treatment failure, and the development of predictive biomarkers and the ability to identify and overcome mechanisms of resistance is vital for optimization of its clinical utility. Additionally, there has been evidence that PARP inhibition may have a therapeutic role beyond HR deficient tumors which warrants further investigation, both as single agent and in combination with other therapeutic modalities like cytotoxic chemotherapy, radiation, targeted therapy and immunotherapy. With new strategies to overcome resistance and expand its therapeutic utility, PARP inhibitors are likely to become a staple in our armamentarium of drugs in cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, resistance inevitably emerges during its clinical application, which can lead to cancer progression and reduced survival rates, posing a substantial challenge in clinical management [31].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 7×
“Olaparib was first shown in simultaneous publications from two independent groups to successfully induce cell killing effects in BRCA-deficient cancer cells through inhibition of DDR [12,13].”
BackgroundInfluentialSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 7×
“Olaparib was first shown in simultaneous publications from two independent groups to successfully induce cell killing effects in BRCA-deficient cancer cells through inhibition of DDR [12,13].”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · cited 1×
“Phase I studies subsequently demonstrated good safety and tolerability up to a dose of 400 mg twice daily, with dose limiting toxicities of grade 4 thrombocytopenia and grade 3 somnolence, and also showed early signals of antitumor activity with a response rate of up to 46% in heavily pre-treated BRCA1/2-mutant cancer…”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882 · cited 1×
“DSBs are repaired through 2 major pathways, the high fidelity HR pathway, and the more error-prone non-homologous end-joining (NHEJ) pathway [7].”
BackgroundPARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 1×
“PARP inhibitors profoundly sensitize cancer cells to DNA damaging agents and act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA1/2 mutations [2].”
BackgroundSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“A systemic screen of cancer cell lines with a large panel of drugs revelaed that Ewing’s sarcoma cells harboring the EWSR10FLI1 gene translocation was exquisitely sensitive to PARP inhibitors [48].”
BackgroundNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451 · cited 1×
“In this study, patients with platinum-sensitive disease were included regardless of germline BRCA1/2 mutation and HR deficiency status, while results were stratified to investigate role of HR deficiency biomarkers for response [27].”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · cited 1×
“for patients with platinum sensitive compared to platinum resistant disease [16,17].”
BackgroundTrapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192 · cited 2×
“Emerging evidence also suggests that in addition to the catalytic action of PARP inhibitors leading to synthetic lethality in HR deficient tumors, PARP inhibitors also causes trapping of PARP1 and PARP2, forming PARP-DNA complexes with increased cytotoxicity leading to increased cell killing [9].”
Background
Cited by
van den Heerik, A. S. V. M., Horeweg, N., de Boer, S. M., Bosse, T., & Creutzberg, C. L. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001822 · Cited by 197
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 188
“Strategies to bypass this resistance may imply alternate dosing of PARP inhibitors or combined administration with platinum derivatives [346].”
BackgroundDNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovicova, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 168
Jain, P. G., & Patel, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.024 · Cited by 142
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 144
Metadata
- Authors
- Lim, J., & Tan, D. S. P.
- Affiliations
- National University Cancer Institute, Singapore (SG)
- Corresponding author
- Tan, David S. P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2017-08-22
- Volume
- 9
- Issue
- 8
- Pages
- 109
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC5575612
- OpenAlex
- W2750488721
- Cited by
- 52
- References
- 78
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 11 · 2021: 5 · 2020: 5 · 2019: 12 · 2018: 7 · 2017: 1
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- PARP inhibitors, synthetic lethality, homologous recombination deficiency, BRCA mutations, drug resistance mechanisms, predictive biomarkers, ovarian cancer, breast cancer, prostate cancer, combination therapy, immunotherapy, targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. https://app.cochat.ai/papers/10.3390/cancers9080109
- The paper
- Lim, J., & Tan, D. S. P. (2017). Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers. https://doi.org/10.3390/cancers9080109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.